Free beta access. 50 free AI tokens each week. Optional top-ups available. See what is included
Opening Word document…

Biopharma innovation is high now due to our current free-market medical structure.

*link & uq combined

Prescient & Strategic Intelligence, September 2022 Biopharmaceutical Market Share Analysis Report by Product Type (Monoclonal Antibodies, Recombinant Growth Factors, Purified Proteins, Recombinant Proteins, Recombinant Hormones, Vaccines), Therapeutic Application (Oncology, Inflammatory and Infectious Diseases, Autoimmune Disorders, Metabolic Disorders, Hormonal Disorders, Cardiovascular Diseases, Neurological Diseases) - Global Industry Demand Forecast to 2030 https://www.psmarketresearch.com/market-analysis/biopharmaceuticals-market#

In 2021, North America was dominant, with a global revenue share of 44%, owing to the high R&D investments, growing adoption of technologically advanced solutions, presence of global players, and their efforts to come up with newer patents. The U.S. holds the major share in this region, which is followed by Europe and Asia-Pacific. With the evolution of biotechnology and conventional pharma sciences, the awareness regarding the best treatments with lower side-effects has also increased. The U.S. leads the global biopharmaceutical R&D list with more than 150,000 studies conducted since 2008, because of the prominence and size of its pharmaceutical sector. Within the country, California accounts for most of the studies, in part, because of its robust tech industry and desire for innovation. Moreover, the U.S. biopharmaceuticals industry has produced more than half the world’s new molecules over the last decade, because of the well-supported intellectual property framework, and government initiatives. Thus, biopharmaceuticals market sales have shown an incredible growth over the past several years in the U.S. The country has been recognized as the innovation capital of the world for life sciences, and its government had put in capital investments since the early stages of pharmaceutical companies. Moreover, it is the biggest investor in health care due to its sizable population, established network of researchers, and expansive health care industry. With regard to medical costs, the U.S. has a free-pricing marketing system. The U.S. prices of biologics are comparatively higher than in other countries, which allows biopharma firms to put in the high R&D funds on these drugs.

Sign in to recut, update, or save this card.